COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    cypress-1
Previous Study | Return to List | Next Study

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (Cypress 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03382899
Recruitment Status : Terminated (The CYPRESS-1 trial was closed early after the planned final analysis because the risk benefit ratio is unfavorable.)
First Posted : December 26, 2017
Last Update Posted : May 6, 2020
ARMO BioSciences
Information provided by (Responsible Party):
Eli Lilly and Company

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : December 6, 2019
Actual Study Completion Date : March 4, 2020